Morepen Laboratories share news, announcements and annual reports
NSE: MOREPENLABBSE: 500288Pharmaceuticals & BiotechnologySmall Cap
Morepen Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 1993 on BSE, Nov 1999 on NSE
Last close ₹125.58down ₹6.60 (4.99%)BSE ₹125.90
Share price at the NSE close on 28 Oct 2026. Previous close ₹132.18.
28 Oct: open ₹128.00, high ₹130.55, low ₹125.58
52-week range of traded prices to 28 Oct 2026
₹33.05Low, 30 Mar 2026₹150.70High, 7 Oct 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,881 Cr1,108th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.98
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.16%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 51,15,994
Morepen Laboratories analyst meets
26 filed, newest first.
May 2025
8 May · Analysts
Feb 2025
3 Feb · Analysts
Nov 2024
6 Nov · Analysts
Aug 2024
9 Aug · Analysts
May 2024
17 May · Analysts
Jan 2024
24 Jan · Analysts
Oct 2023
30 Oct · Analysts
May 2022
Feb 2022
7 Feb · Analysts
Nov 2021
10 Nov · Analysts
Jul 2021
31 Jul · Analysts
26 Jul · Analysts
May 2021
6 May · Analysts
2 May · Analysts
Feb 2021
20 Feb · Analysts
12 Feb · Analysts
Nov 2020
17 Nov · Analysts
7 Nov · Analysts
Aug 2020
31 Aug · Analysts
Jun 2020
24 Jun · Analysts
May 2019
22 May · Analysts
6 May · Analysts
Jun 2018
25 Jun · Analysts
May 2018
16 May · Analysts
Feb 2018
2 Feb · Analysts
Jan 2018
22 Jan · Analysts